Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
In patients with Core Binding Factors Acute Myelogenous Leukemia, the level of Minimal
Residual Disease after chemotherapy is predictive of relapse. The relapse risk is also
increased in case of mutations of receptors tyrosine kinase. For patients with a high Minimal
Residual Disease level at the end of consolidation or in molecular relapse, maintenance by
the inhibitor dasatinib is proposed.